{"id":33348,"date":"2014-10-09T08:20:27","date_gmt":"2014-10-09T12:20:27","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=33348"},"modified":"2014-10-09T08:20:27","modified_gmt":"2014-10-09T12:20:27","slug":"arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348","title":{"rendered":"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 <strong>Arrowhead Research Corp (NASDAQ:ARWR)<\/strong> experimental hepatitis B therapy data disappointed the investors following which the stocks of Arrowhead plummeted more than 40%. In the phase II study conducted, the experimental drug ARC-520 resulted in a 0.3 log reduction in HBsAG when dosed at 2 mg\/kg. HBsAG indicates the presence of hepatitis virus in the human body.<\/p>\n<p style=\"text-align: justify;\"><strong>The expectations and performance<\/strong><\/p>\n<p style=\"text-align: justify;\">The treatment result came lower compared to investors expectations. In August, Arrowhead Research Corp (NASDAQ:ARWR) hinted that the reduction from therapy was closer to 1 log. However, the revealed data of 0.3log is much lower than 1-log reduction. The data released on ARC-520 was contained in a later-breaker abstract for AASLD annual meeting. It is scheduled to be held in November. A Phase II study of Arrowhead\u2019s experimental drugARC-520 is ongoing. As of now, Arrowhead is testing with higher doses of ARC-520. It needs to be seen if the higher doses can have a positive impact or not. Arrowhead Research Corp (NASDAQ:ARWR) has yet not disclosed the results from higher doses treatment of ARC-520.<\/p>\n<p style=\"text-align: justify;\"><strong>The study<\/strong><\/p>\n<p style=\"text-align: justify;\">The impact of ARC-520 is seen by measuring the change of HBsAg decline from baseline in percentage terms. The patients who were treated with ARC-520 in cohort 1, mean nadir came at -39% with a mean change of -31% on day 85. The patients who were treated with ARC-520 in cohort 2, mean nadir HBsAg came at &#8211; 51%with a mean change of -22% on day 85. If the results in cohort 2 are analyzed, the reduction in HBsAG measured in percentage terms was statistically significant versus placebo for three days through 43 post dose.<\/p>\n<p style=\"text-align: justify;\">For the first time, a reduction in HBsAg resulted through RNA interference has been displayed in chronic HBV patients. A specific formula is used to calculate the change in HBsAg decline from baseline and to convert it into a log reduction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 Arrowhead Research Corp (NASDAQ:ARWR) experimental hepatitis B therapy data disappointed the investors following which the stocks of Arrowhead plummeted more [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":16660,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[3139,3137,3138],"stock_ticker":[],"class_list":["post-33348","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-arrowhead-research-corp","tag-arrowhead-research-corp-nasdaqarwr","tag-nasdaqarwr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 Arrowhead Research Corp (NASDAQ:ARWR) experimental hepatitis B therapy data disappointed the investors following which the stocks of Arrowhead plummeted more [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-09T12:20:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"176\" \/>\n\t<meta property=\"og:image:height\" content=\"161\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints\",\"datePublished\":\"2014-10-09T12:20:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348\"},\"wordCount\":319,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg\",\"keywords\":[\"Arrowhead Research Corp\",\"Arrowhead Research Corp (NASDAQ:ARWR)\",\"NASDAQ:ARWR\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348\",\"name\":\"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg\",\"datePublished\":\"2014-10-09T12:20:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg\",\"width\":176,\"height\":161},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348","og_locale":"en_US","og_type":"article","og_title":"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints - Wall Street PR","og_description":"Boston, MA 10\/09\/2014 (wallstreetpr) \u2013 Arrowhead Research Corp (NASDAQ:ARWR) experimental hepatitis B therapy data disappointed the investors following which the stocks of Arrowhead plummeted more [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-10-09T12:20:27+00:00","og_image":[{"width":176,"height":161,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints","datePublished":"2014-10-09T12:20:27+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348"},"wordCount":319,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg","keywords":["Arrowhead Research Corp","Arrowhead Research Corp (NASDAQ:ARWR)","NASDAQ:ARWR"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348","url":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348","name":"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg","datePublished":"2014-10-09T12:20:27+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Arrowhead-Research-Corp.jpg","width":176,"height":161},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/arrowhead-research-corp-nasdaqarwrs-arc-520-data-disappoints-33348#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Arrowhead Research Corp (NASDAQ:ARWR)\u2019s ARC-520 Data Disappoints"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33348","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=33348"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/33348\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/16660"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=33348"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=33348"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=33348"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=33348"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}